Cargando…
The beta-3 adrenergic agonist (CL-316,243) restores the expression of down-regulated fatty acid oxidation genes in type 2 diabetic mice
BACKGROUND: The hallmark of Type 2 diabetes (T2D) is hyperglycemia, although there are multiple other metabolic abnormalities that occur with T2D, including insulin resistance and dyslipidemia. To advance T2D prevention and develop targeted therapies for its treatment, a greater understanding of the...
Autores principales: | Kumar, Amit, Shiloach, Joseph, Betenbaugh, Michael J, Gallagher, Emily J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4362840/ https://www.ncbi.nlm.nih.gov/pubmed/25784953 http://dx.doi.org/10.1186/s12986-015-0003-8 |
Ejemplares similares
-
CL316,243, a β3-adrenergic receptor agonist, induces muscle hypertrophy and increased strength
por: Puzzo, Daniela, et al.
Publicado: (2016) -
Apparent histological changes of adipocytes after treatment with CL 316,243, a β-3-adrenergic receptor agonist
por: Ghorbani, Masoud, et al.
Publicado: (2015) -
Anti Diabetic effect of CL 316,243 (A β3-Adrenergic Agonist) by Down Regulation of Tumour Necrosis Factor (TNF-α) Expression
por: Ghorbani, Masoud, et al.
Publicado: (2012) -
The glucose lowering effects of CL 316,243 dissipate with repeated use and are rescued bycilostamide
por: Medak, Kyle D., et al.
Publicado: (2022) -
Comparative Transcriptome Profiling of Cold Exposure and β3-AR Agonist CL316,243-Induced Browning of White Fat
por: Li, Yu, et al.
Publicado: (2021)